Skip to main content
Top
Published in: Tumor Biology 9/2016

01-09-2016 | Original Article

Overexpression of MYCN promotes proliferation of non-small cell lung cancer

Authors: Kun Liu, Shuo Wang, Yifei Liu, Jun Gu, Shudong Gu, Zhen Xu, Rui Zhang, Zhiwen Wang, Huaci Ma, Yingying Chen, Lili Ji

Published in: Tumor Biology | Issue 9/2016

Login to get access

Abstract

V-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) is an oncogene that is known amplified and overexpressed in different human malignancies including small cell lung cancer. However, the role of MYCN in non-small cell lung cancer (NSCLC) development remains elusive. In the present study, Western blot and immunohistochemistry assays demonstrated that MYCN was overexpressed in NSCLC tumor tissues and cell lines. In addition, immunohistochemistry analysis revealed that upregulation of MYCN expression was positively correlated with a more invasive tumor phenotype and poor prognosis. In vitro studies using serum starvation-refeeding experiment and MYCN-siRNA transfection assay demonstrated that MYCN expression promoted proliferation of NSCLC cells, while MYCN knockdown led to decreased cell growth resulted from growth arrest of cell cycle at G0/G1 phase. Furthermore, upregulation and knockdown of sex-determining region Y-box 2 (SRY) (SOX2), which was a well-known oncogene, confirmed that MYCN might be a downstream gene of the transcription factor SOX2. Collectively, our finding suggested that MYCN might contribute to the progression of NSCLC by enhancing cell proliferation, and that targeting MYCN might provide beneficial effects for the clinical therapy of NSCLC.
Literature
1.
2.
3.
go back to reference Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):740–801.PubMed Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):740–801.PubMed
4.
go back to reference Chen G, Yi XH. Pathology and genetics of disease and tumours of the lung, pleura in China. Zhonghua Bing Li Xue Za Zhi. 2005;34(8):490–3.PubMed Chen G, Yi XH. Pathology and genetics of disease and tumours of the lung, pleura in China. Zhonghua Bing Li Xue Za Zhi. 2005;34(8):490–3.PubMed
5.
go back to reference Ravdin PM, Davis G. Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables. Lung Cancer. 2006;52(2):207–12.CrossRefPubMed Ravdin PM, Davis G. Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables. Lung Cancer. 2006;52(2):207–12.CrossRefPubMed
6.
go back to reference Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000;16:653–99.CrossRefPubMed Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000;16:653–99.CrossRefPubMed
8.
go back to reference Nau MM, Brooks Jr BJ, Carney DN, Gazdar AF, Battey JF, et al. Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci U S A. 1986;83(4):1092–6.CrossRefPubMedPubMedCentral Nau MM, Brooks Jr BJ, Carney DN, Gazdar AF, Battey JF, et al. Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci U S A. 1986;83(4):1092–6.CrossRefPubMedPubMedCentral
9.
go back to reference Engelen E, Akinci U, Bryne JC, Hou J, Gontan C, et al. Sox2 cooperates with Chd7 to regulate genes that are mutated in human syndromes. Nat Genet. 2011;43(6):607–11.CrossRefPubMed Engelen E, Akinci U, Bryne JC, Hou J, Gontan C, et al. Sox2 cooperates with Chd7 to regulate genes that are mutated in human syndromes. Nat Genet. 2011;43(6):607–11.CrossRefPubMed
10.
go back to reference Liu K, Lin B, Zhao M, Yang X, Chen M, et al. The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal. 2013;25(5):1264–71.CrossRefPubMed Liu K, Lin B, Zhao M, Yang X, Chen M, et al. The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal. 2013;25(5):1264–71.CrossRefPubMed
11.
go back to reference Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, et al. SOX2 is an amplified lineage-survual oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41(11):1238–42.CrossRefPubMedPubMedCentral Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, et al. SOX2 is an amplified lineage-survual oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41(11):1238–42.CrossRefPubMedPubMedCentral
12.
go back to reference Hussenet T, Dali S, Exinger J, Monga B, Jost B, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung cell carcinomas. PLoS One. 2010;5(1):e8960.CrossRefPubMedPubMedCentral Hussenet T, Dali S, Exinger J, Monga B, Jost B, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung cell carcinomas. PLoS One. 2010;5(1):e8960.CrossRefPubMedPubMedCentral
13.
go back to reference Rudin CM1, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44(10):1111–6.CrossRefPubMedPubMedCentral Rudin CM1, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44(10):1111–6.CrossRefPubMedPubMedCentral
14.
go back to reference Wan C, Hou S, Ni R, Lv L, Ding Z, et al. MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability. Oncogene. 2015;34(2):237–45.CrossRefPubMed Wan C, Hou S, Ni R, Lv L, Ding Z, et al. MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability. Oncogene. 2015;34(2):237–45.CrossRefPubMed
15.
go back to reference Wang Y, Liu F, Mao F, Hang Q, Huang X, et al. Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration. J Biol Chem. 2013;288(13):9028–34.CrossRefPubMedPubMedCentral Wang Y, Liu F, Mao F, Hang Q, Huang X, et al. Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration. J Biol Chem. 2013;288(13):9028–34.CrossRefPubMedPubMedCentral
16.
go back to reference Ji L, Li H, Gao P, Shang G, Zhang DD, Zhang N, et al. Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One. 2013;8(5):e63404.CrossRefPubMedPubMedCentral Ji L, Li H, Gao P, Shang G, Zhang DD, Zhang N, et al. Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One. 2013;8(5):e63404.CrossRefPubMedPubMedCentral
17.
go back to reference Wang Y, Wang Y, Xiang J, Ji F, Deng Y, et al. Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer. Cancer Lett. 2014;343(1):6–13.CrossRefPubMed Wang Y, Wang Y, Xiang J, Ji F, Deng Y, et al. Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer. Cancer Lett. 2014;343(1):6–13.CrossRefPubMed
18.
go back to reference Wang Y, Yang S, Ni Q, He S, Zhao Y, et al. Overexpression of forkhead box J2 can decrease the migration of breast cancer cells. J Cell Biochem. 2012;113(8):2729–37.CrossRefPubMed Wang Y, Yang S, Ni Q, He S, Zhao Y, et al. Overexpression of forkhead box J2 can decrease the migration of breast cancer cells. J Cell Biochem. 2012;113(8):2729–37.CrossRefPubMed
19.
go back to reference Wood SL, Pernemalm M, Crosbie PA, Whetton AD. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40(4):558–66.CrossRefPubMed Wood SL, Pernemalm M, Crosbie PA, Whetton AD. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40(4):558–66.CrossRefPubMed
20.
go back to reference Bell E, Chen L, Liu T, Marshall GM, Lunec J, et al. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett. 2010;293(2):144–57.CrossRefPubMed Bell E, Chen L, Liu T, Marshall GM, Lunec J, et al. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett. 2010;293(2):144–57.CrossRefPubMed
21.
go back to reference Woo CW, Tan F, Cassano H, Lee J, Lee KC, et al. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma. Pediatr Blood Cancer. 2008;50(2):208–12.CrossRefPubMed Woo CW, Tan F, Cassano H, Lee J, Lee KC, et al. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma. Pediatr Blood Cancer. 2008;50(2):208–12.CrossRefPubMed
22.
go back to reference Feng C, Wang T, Tang R, Wang J, Long H, et al. Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells. Pediatr Surg Int. 2010;26(12):1185–91.CrossRefPubMed Feng C, Wang T, Tang R, Wang J, Long H, et al. Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells. Pediatr Surg Int. 2010;26(12):1185–91.CrossRefPubMed
23.
go back to reference Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S, et al. Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol. 2007;30(5):1189–96.PubMed Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S, et al. Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol. 2007;30(5):1189–96.PubMed
24.
go back to reference Malynn BA, de Alboran IM, O’Hagan RC, Bronson R, Davidson L, et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev. 2000;14(11):1390–9.PubMedPubMedCentral Malynn BA, de Alboran IM, O’Hagan RC, Bronson R, Davidson L, et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev. 2000;14(11):1390–9.PubMedPubMedCentral
25.
go back to reference Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, et al. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol Carcinog. 2011;50(6):403–11.CrossRefPubMed Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, et al. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol Carcinog. 2011;50(6):403–11.CrossRefPubMed
27.
go back to reference Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.CrossRefPubMed Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.CrossRefPubMed
Metadata
Title
Overexpression of MYCN promotes proliferation of non-small cell lung cancer
Authors
Kun Liu
Shuo Wang
Yifei Liu
Jun Gu
Shudong Gu
Zhen Xu
Rui Zhang
Zhiwen Wang
Huaci Ma
Yingying Chen
Lili Ji
Publication date
01-09-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5236-2

Other articles of this Issue 9/2016

Tumor Biology 9/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine